Attovia Therapeutics, Inc.(ATTO)

Biotechnology · San Carlos, CA

$18.00+0.00 (+0.03%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

PB Ratio: N/A

Basis: FMP quote market capitalization / book value attributable to common shareholders (matching reported total stockholders equity minus preferred stock). Source: stored company filings and market data; unavailable inputs remain N/A.

The P/B ratio is N/A as of 2026-10-06T15:40:57.372Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:40:57.372Z.

Quote observation: 2026-10-06T15:40:21.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 774,540,000
Total stockholders equity · period ending 2026-06-30: 112,767,000
Preferred stock · period ending 2026-06-30: 258,226,000
Book value attributable to common shareholders · period ending 2026-06-30: -145,459,000

FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd

P/E Ratio|ROE|Debt to Equity|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ATTO PB Ratio Metrics

PB RATIO

N/A

ATTO Competitors' PB Ratio

ATTO

Attovia Therapeutics, Inc.

Current

Market Cap

$774.54M

PB Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LXRX

Lexicon Pharmaceuticals, Inc.

vs ATTO

Market Cap

$785.87M

PB Ratio

4.50

TTM Avg

4.64

3Y Avg

3.11

5Y Avg

3.40

MLAB

Mesa Laboratories, Inc.

vs ATTO

Market Cap

$773.58M

PB Ratio

4.10

TTM Avg

2.88

3Y Avg

2.93

5Y Avg

2.84

GERN

Geron Corporation

vs ATTO

Market Cap

$789.07M

PB Ratio

3.61

TTM Avg

3.99

3Y Avg

5.25

5Y Avg

5.58

DSGN

Design Therapeutics, Inc.

vs ATTO

Market Cap

$769.08M

PB Ratio

3.81

TTM Avg

3.19

3Y Avg

1.68

5Y Avg

1.76

AHCO

AdaptHealth Corp.

vs ATTO

Market Cap

$795.49M

PB Ratio

0.58

TTM Avg

0.85

3Y Avg

0.83

5Y Avg

0.96

GYRE

Gyre Therapeutics, Inc.

vs ATTO

Market Cap

$799.93M

PB Ratio

7.41

TTM Avg

6.97

3Y Avg

13.51

5Y Avg

13.33

APMD

Apnimed, Inc.

vs ATTO

Market Cap

$804.43M

PB Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INMD

InMode Ltd.

vs ATTO

Market Cap

$805.59M

PB Ratio

1.28

TTM Avg

1.39

3Y Avg

1.80

5Y Avg

4.16

CADL

Candel Therapeutics, Inc.

vs ATTO

Market Cap

$752.48M

PB Ratio

5.97

TTM Avg

4.72

3Y Avg

7.10

5Y Avg

4.64

NAME	MARKET CAP	PB RATIO	TTM	3Y	5Y
Attovia Therapeutics, Inc. (ATTO)	$774.54M	N/A	N/A	N/A	N/A
Lexicon Pharmaceuticals, Inc. (LXRX)vs ›	$785.87M	4.50	4.64	3.11	3.40
Mesa Laboratories, Inc. (MLAB)vs ›	$773.58M	4.10	2.88	2.93	2.84
Geron Corporation (GERN)vs ›	$789.07M	3.61	3.99	5.25	5.58
Design Therapeutics, Inc. (DSGN)vs ›	$769.08M	3.81	3.19	1.68	1.76
AdaptHealth Corp. (AHCO)vs ›	$795.49M	0.58	0.85	0.83	0.96
Gyre Therapeutics, Inc. (GYRE)vs ›	$799.93M	7.41	6.97	13.51	13.33
Apnimed, Inc. (APMD)vs ›	$804.43M	N/A	N/A	N/A	N/A
InMode Ltd. (INMD)vs ›	$805.59M	1.28	1.39	1.80	4.16
Candel Therapeutics, Inc. (CADL)vs ›	$752.48M	5.97	4.72	7.10	4.64

Book Value Analysis

P/B Ratio

N/A

Market Price / Book Value per Share

PB Ratio Formula & Definition

PB Ratio = Market Cap / (Total Shareholders' Equity − Preferred Stock)

The price-to-book ratio compares market capitalization to book value attributable to common shareholders (total equity minus preferred stock). Lower values can indicate a cheaper valuation relative to net assets.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PB Ratio: N/A

ATTO PB Ratio Metrics

ATTO Competitors' PB Ratio

Book Value Analysis

PB Ratio Formula & Definition

Related Metrics